EN 简
EN 简

Press Release

JW Therapeutics Announces IND Approval for the Clinical Trial of JWCAR129
27 September, 2021
JW Therapeutics Announces Updated 1-year Follow-up Result of Relmacabtagene Autoleucel Injection At the 24th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)
26 September, 2021
JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in China
06 September, 2021
JW Therapeutics Announces 2021 Interim Results
27 August, 2021
JW Therapeutics Announces Strategic Partnership with MediTrust Health
20 August, 2021
JW Therapeutics Announces 2020 Annual Results
26 March, 2021
JW Therapeutics and Thermo Fisher Scientific Announce CAR-T Partnership in China
03 February, 2021
JW Therapeutics Presents Data from Pivotal Trial of Relma-cel at the 62nd ASH Annual Meeting
07 December, 2020
Leading Cell Therapy Company JW Therapeutics Lists on Main Board of HKEX
03 November, 2020
JW Therapeutics and Lyell Immunopharma Announce Collaboration to Advance Solid Tumor Treatment in China
10 August, 2020
JW Acquires Syracuse Biopharma
20 July, 2020
JW Therapeutics Completes $ 100 Million Series B Financing
09 June, 2020
JW Therapeutics announced the grand opening of R&D center in Zhangjiang Science City of Pudong New Area, Shanghai
12 December, 2018
JW Therapeutics to Build Its First Commercial CAR-T Cell Manufacturing Plant in Suzhou, China
10 August, 2018
JW Therapeutics Closes $ 90 Million Series A Financing
08 March, 2018